BAF57在结直肠癌组织中的表达及其对患者预后的影响

doi:10.3969/j.issn.1004-616x.2024.05.007

摘要/Abstract

摘要： 目的： 探讨Brahma相关基因1相关因子57(BAF57)在结直肠癌(CRC)组织中的表达及其对患者预后的影响。方法： 选择2016年1月—2018年1月河北省衡水市人民医院收治的110例CRC患者的癌组织和癌旁组织作为研究对象，分别采用荧光定量PCR (qPCR)和Western blot方法检测癌及癌旁组织中BAF57的mRNA和蛋白表达，分析CRC癌组织中BAF57表达水平与临床病理指标的关系；采用受试者工作特征(ROC)曲线分析BAF57表达水平诊断CRC的价值，以癌组织中BAF57表达水平均值为基准，将患者分为高低表达组。采用Kaplan-Meier和Log-rank检验进行BAF57高、低表达水平组间的生存分析。结果： CRC癌组织中BAF57 mRNA和蛋白的表达水平均显著高于癌旁组织(P<0.05)，且其表达水平与患者的TNM分期均呈正相关(r分别为0.913和0.925，均为P<0.01)，与癌组织分化程度呈负相关(r分别为-0.781和-0.888，均为P<0.01)；与淋巴结转移呈正相关性(r分别为0.744和0.743，均为P<0.01)。ROC分析显示，BAF57 mRNA和蛋白诊断CRC的曲线下面积分别为0.976和0.915。生存分析表明，BAF57 mRNA和蛋白高表达组的中位生存时间均明显短于低表达组，差异均有统计学意义(均为P<0.05)。结论： BAF57在CRC组织中高表达，且与患者恶性进展及不良预后呈正相关，BAF57有望成为CRC患者预后不良的预测指标。

关键词: 结直肠癌, BAF57, 临床病理, 预后

Abstract: OBJECTIVE： To investigate the expression of Brahma-related gene 1-associated factor 57 (BAF57) in colorectal cancer (CRC) tissues and its impact on prognosis of patients. METHODS： The cancer and adjacent tissues of 110 CRC patients admitted to our hospital from January 2016 to January 2018 were selected as the study subjects. BAF57 expression was detected by Western blot and qPCR，respectively. Relationships between BAF57 expression levels and pathological parameters in the tissues were analyzed. Receiver operating characteristic curve and subject operator (ROC) curve were used to determine the relationships between BAF57 expression and diagnosis value. Survival time was analyzed by Kaplan-Meier and Log-rank. RESULTS： The BAF57 mRNA and protein levels were significantly higher in the CRC than those in the adjacent tissues (P<0.05). Both levels were positively correlated with TNM stages (r=0.913，P<0.01；r=0.925，P<0.01)， negatively related with tissue differentiation (r=-0.781，P<0.01；r=-0.888，P<0.01)；and positively with lymph node metastasis (r=0.744，P<0.01；r=0.743，P<0.01). ROC analysis showed that the area under the curve for BAF57 mRNA and protein for CRC diagnosis was 0.976 and 0.915，respectively. Survival analysis indicated that the median survival time of the BAF57 mRNA high-expression group (48.5 month) was significantly lower than the low-expression group (60.5 month，Log-rank χ²=4.985，P<0.05)，which was also found between the protein high- and low-expression groups (46.5 and 60.0 months，respectively；Log-rank χ²=4.469，P<0.05). CONCLUSION： BAF57 was highly expressed in CRC tissues and was positively associated with malignant progression and poor prognosis in patients.

Key words: colorectal cancer, BAF57, clinicopathology, prognosis

中图分类号:

R735.3

康晓培, 郭振江, 刘防震. BAF57在结直肠癌组织中的表达及其对患者预后的影响[J]. 癌变·畸变·突变, 2024, 36(5): 379-383.

KANG Xiaopei, GUO Zhenjiang, LIU Fangzhen. The expression and prognosis of BAF57 in colorectal cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 379-383.

参考文献

[1] BAIDOUN F, ELSHIWY K, ELKERAIE Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009.
[2] BAIDOUN F. Colorectal cancer epidemiology: recent trends and impact on outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009.
[3] PATEL S G, KARLITZ J J, YEN T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 262-274.
[4] PIAWAH S, VENOOK A P. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer, 2019, 125(23): 4139-4147.
[5] ZYGULSKA A L, PIERZCHALSKI P. Novel diagnostic biomarkers in colorectal cancer[J]. Int J Mol Sci, 2022, 23(2): 852.
[6] LOMELí H, CASTILLO-ROBLES J. The developmental and pathogenic roles of BAF57, a special subunit of the BAF chromatin-remodeling complex[J]. FEBS Lett, 2016, 590(11): 1555-1569.
[7] KAGAMI S, KURITA T, KAWAGOE T, et al. Prognostic significance of BAF57 expression in patients with endometrial carcinoma[J]. Histol Histopathol, 2012, 27(5): 593-599.
[8] 陈功, 邱萌, 张俊. 结直肠癌规范化诊疗: 国际进展与中国实践荟萃[M]. 长沙: 中南大学出版社, 2015: 83-85.
[9] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[10] ZHENG R, ZHANG S W, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2(1): 1-9.
[11] PATEL S G, AHNEN D J. Colorectal cancer in the young[J]. Curr Gastroenterol Rep, 2018, 20(4): 15.
[12] YOUNIS N K, ROUMIEH R, BASSIL E P, et al. Nanoparticles: attractive tools to treat colorectal cancer[J]. Semin Cancer Biol, 2022, 86(Pt 2): 1-13.
[13] WENG J Y, LI S B, ZHU Z L, et al. Exploring immunotherapy in colorectal cancer[J]. J Hematol Oncol, 2022, 15(1): 95.
[14] ZHAO H, MING T Q, TANG S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1): 144.
[15] MARTELLI V, PASTORINO A, SOBRERO A F. Prognostic and predictive molecular biomarkers in advanced colorectal cancer[J]. Pharmacol Ther, 2022, 236: 108239.
[16] GLASS S E, COFFEY R J. Recent advances in the study of extracellular vesicles in colorectal cancer[J]. Gastroenterology, 2022, 163(5): 1188-1197.
[17] HEO Y, PARK J H, KIM J, et al. Crystal structure of the HMG domain of human BAF57 and its interaction with four-way junction DNA[J]. Biochem Biophys Res Commun, 2020, 533(4): 919-924.
[18] FENG J G, XU X C, FAN X, et al. BAF57/SMARCE1 interacting with splicing factor SRSF1 regulates mechanical stress-induced alternative splicing of cyclin D1[J]. Genes, 2021, 12(2): 306.
[19] SOUSLOVA T, MIRéDIN K, MILLAR A M, et al. Recruitment by the repressor Freud-1 of histone deacetylase-Brg1 chromatin remodeling complexes to strengthen HTR1A gene repression[J]. Mol Neurobiol, 2017, 54(10): 8263-8277.
[20] LINK K A, BALASUBRAMANIAM S, SHARMA A, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity[J]. Cancer Res, 2008, 68(12): 4551-4558.
[21] YAMAGUCHI T, KURITA T, NISHIO K, et al. Expression of BAF57 in ovarian cancer cells and drug sensitivity[J]. Cancer Sci, 2015, 106(4): 359-366.
[22] RUDOLPH A, TOTH C, HOFFMEISTER M, et al. Expression of oestrogen receptor β and prognosis of colorectal cancer[J]. Br J Cancer, 2012, 107(5): 831-839.
[23] 裴家强, 游波, 游凯, 等. PET/CT联合血清HE4、ESM-1在肺癌诊断中的应用价值[J]. 河北医药, 2020, 42(14): 2125-2128.
[24] 李文利, 王静, 孙务霞. CK20、CDX2、CK7组织表达水平对结直肠癌术后疗效及预后的预测价值[J]. 哈尔滨医药, 2024, 10(1): 14-16.